Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 14/20 | 0.51 |
| ▸ | PGR | P06401 | 10/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075244 | 0.86 | NR3C1 (0.46) | NR3C1NR3C2PGR | |
| SCHEMBL4468142 | 0.85 | NR3C1 (0.59) | NR3C1NR3C2PGR | |
| SCHEMBL292772 | 0.82 | NR3C1 (0.57) | NR3C1NR3C2PGR | |
| SCHEMBL4476759 | 0.79 | NR3C1 (0.49) | NR3C1NR3C2PGR | |
| SCHEMBL4474712 | 0.78 | NR3C1 (0.68) | NR3C1NR3C2PGR | |
| SCHEMBL5078470 | 0.78 | NR3C1 (0.53) | NR3C1NR3C2PGR | |
| SCHEMBL4478697 | 0.76 | NR3C1 (0.77) | NR3C1NR3C2PGR | |
| SCHEMBL4490215 | 0.74 | NR3C1 (0.55) | NR3C1NR3C2PGR | |
| SCHEMBL4486785 | 0.73 | NR3C1 (0.79) | NR3C1NR3C2PGR | |
| SCHEMBL292180 | 0.72 | NR3C1 (0.54) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | NR3C1 1/4885NR3C2 9/4885PGR 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.